Erythropoietic protoporphyria (EPP) is an inherited disorder that results from partial deficiency of ferrochelatase (FECH), the terminal enzyme of haem biosynthesis. Current methods that examine the exons and their flanking regions of the FECH gene fail to identify mutations in about one in seven of families with EPP. The presence in some families of intragenic deletions that are not identifiable by current methods for sequencing the FECH gene may partly explain the low sensitivity of mutation detection in EPP. Here we describe the identification by gene dosage analysis of a deletion of exons 3 and 4 in a family with EPP in whom a mutation had not been found by sequencing-based methods.
Erythropoietic protoporphyria (EPP) is a genetically determined disease caused by mutations in the gene encoding ferrochelatase (FECH), the enzyme that catalyses the insertion of ferrous iron into protoporphyrin IX to form haem. In EPP, reduction of the activity of this enzyme leads to overproduction of protoporphyrin, which accumulates in red cells, plasma, skin and liver, and gives rise to the clinical manifestations of painful cutaneous photosensitivity and, rarely, liver failure. 1 Although the diagnosis is based on plasma and erythrocyte protoporphyrin measurement, DNA analysis has proved helpful, particularly for preconceptual genetic counselling.
The human FECH gene contains 11 exons, spanning approximately 45 kb. Over 80 FECH mutations have been identi¢ed in EPP and are distributed throughout the gene. 2 The mode of inheritance of EPP is complex. Clinical expression of the disease is associated with FECH activity in the region of 10--30% of normal, less than the 50% expected for a purely autosomal dominant condition. 1 Molecular studies have revealed that co-inheritance of an allelic variant and a severe FECH mutation is required for clinical expression of the disease. 3 This variant contains a C nucleotide in place of a T nucleotide at a polymorphic site (IVS3-48C/T) in intron 3. The presence of the C nucleotide leads to the increased use of an alternative splice site that introduces a premature stop codon. This low expression variant is present in 13% of the UK population, and genotyping families with EPP for this polymorphism is a useful adjunct to genetic counselling for this disorder. 3, 4 Current methods of mutational analysis that target the coding regions of the gene fail to identify FECH mutations in about 14% of patients with EPP. 4, 5 This could be due to intragenic deletions or mutations that are present deep within the introns or underlying primer sites, which would not be recognized by these methods. Intragenic deletions are di⁄cult to identify in the presence of a normal allele. A polymerase chain reaction (PCR) product will be ampli¢ed and it is only by quantitative analysis that it can be determined whether this product arises from a single copy of the gene or the normal two. Here we report the use of gene dosage analysis of individual exons to identify and characterize a 4.4 kb deletion within the FECH gene in a family in whom a mutation was not identi¢ed by PCR ampli¢cation and direct sequencing of genomic DNA.
Materials and methods
Erythrocyte and plasma porphyrins were analysed as described. 6 Genomic DNAwas extracted from whole blood, using the QIAamp DNA puri¢cation kit for sequencing or the Flexigene DNA puri¢cation kit for dosage analysis (Qiagen, Crawley, West Sussex, UK). All exons and 30--300 bp of £anking sequence of the FECH gene were PCR ampli¢ed and sequenced 4 including the IVS3-48 T/C dimorphism. For gene dosage analysis, a multiplex PCR was designed to simultaneously amplify exons 2--9 and 11 of the FECH gene, along with internal controls (primer sequences available from the authors on request). Exon 10 did not amplify consistently within the multiplex so was analysed separately. A £uorescent label was incorporated into each amplicon, allowing subsequent £uorescent detection using an ABI Prism 310 genetic analyser (PE Applied Biosystems, Cheshire, UK). Ampli¢cation was carried out using a Qiagen Multiplex PCR kit with 0.5--2 mg of DNA and 0.5--1.5 pmol (¢nal concentration) of each of 12 pairs of primers in a 20 mL reaction. An initial denaturation of 15 min at 951C was followed by 20 cycles of denaturation for 30 s at 941C, annealing for 1min 30 s at 641C, and extension for 1min 30 s at 721C, with a ¢nal extension for 10 min at 721C.
The PCR products (2 mL) were added to a mixture containing formamide (10 mL) and GS500 standard (0.3 mL) (PE Applied Biosystems, Cheshire, UK) and denatured at 951C for 3 min. The samples were run on the ABI Prism 310 analyser at 601C using POP4 polymer (PE Applied Biosystems, Cheshire, UK).
To determine the gene dosage for each exon, the peak areas were compared with each other and against sexmatched controls. A locus with a double copy will give a theoretical value of 1.0 whereas a locus with a deletion will give a value of 0.5 or 2.0, depending on whether the deleted locus is the numerator or denominator. 7 Fluorescent amplicons from the X-linked genes MECP2 and DMD genes were used as internal controls.
To identify the breakpoints of the deletion, pairs of primers were designed for quantitative PCR of introns 2 and 4 (primer sequences available from the authors on request). These amplicons were multiplexed with internal controls and analysed for dosage. The results indicated whether each amplicon was within the deleted region. Pairs of primers were redesigned at increasing or decreasing distance from the deletion, depending on these results, partially localizing the deletion. The forward primer from the dizygous region of intron 2 (CACATCTTCAGTGCAGTTGC) was used with the antisense primer from the intron 4 dizygous amplicon (AGATGCACTGTGGCATGCAC) to amplify a PCR product straddling the deletion. This amplicon was sequenced and the breakpoints were identi¢ed. 8 
Case report
A four-year-old boy presented with a two-year history of discomfort and itch a¡ecting his skin following sun exposure, but no associated rash. There was no other medical history of note, apart from eczema since infancy. His mother reported a history of blistering a¡ecting her neck and arms following sun exposure and his paternal aunt has a history of burning of her skin during the summer months.
On examination, there was an erythematous discolouration of the dorsal aspect of his hands, which showed a sharp cut-o¡ at the wrists consistent with photosensitivity. There were no scars. General examination was normal; in particular, there was no hepatosplenomegaly.
Investigations revealed a mild microcytic anaemia: Hb 11.1g/dL (12--14 g/dL), mean corpuscular volume (MCV) 74 fL (76--100 fL). Serum iron was normal, total iron-binding capacity (TIBC) 72 mmol/L (45--70 mmol/ L), ferritin 11 mg/L (18--280 mg/L). Aspartate transaminase (AST) was raised (84 U/L; reference range 10--40 U/L). All other liver function tests were normal. Autoantibody screen, hepatitis B and C antigen, faecal occult blood and coeliac screen were all negative. An ultrasound of the liver was normal. Whole blood porphyrin was 9.8 mmol/L red blood corpuscles (RBCs) (reference range 0--2 mmol/L) and a diagnosis of EPP was made. Faecal and urinary porphyrins were negative.
Treatment was commenced with sunblock cream, advice regarding sun care was given and a light ¢ltering ¢lm was ¢tted to the windows of the family car. A trial of beta-carotene was initiated but was of no bene¢t. Liver function continues to be monitored and AST has remained elevated (ranging from 60--92 U/L). His parents requested further information on the probability of future o¡spring developing EPP and samples were referred for genetic testing when he was 8 years old.
Results and discussion
The diagnosis of EPP was con¢rmed for the proband by demonstrating an increased erythrocyte total porphyrin (23.7 mmol/L; reference range: 0.4--1.7), which was mainly free protoporphyrin and increased plasma porphyrin with a £uorescence emission peak at 632 nm. Both parents had normal erythrocyte and plasma porphyrin concentrations.
Bidirectional sequencing of all 11 exons and £anking intronic regions of the ferrochelatase gene failed to identify a mutation in the proband.
DNA samples from the proband and his parents were analysed for the FECH IVS3-48T/C low expression polymorphism. Genotype analysis of his mother demonstrated heterozygosity (C/T) for the IVS3-48 dimorphism. The father appeared to be homozygous (T/T) and the proband homozygous (C/C). The apparent homozygosity of father and son for di¡erent alleles suggested either non-paternity or the presence in both of a FECH deletion that included the dimorphic site and one or both of the primer sites used for its ampli¢cation. A deletion of this type creates hemizygosity at this locus, leading to ampli¢cation of only one allele, that trans to the deletion, giving an appearance on sequencing that is indistinguishable from homozygosity.
Further investigation was designed to determine the possible presence of an FECH deletion in the proband and his father. Fluorescence gene dosage analysis iden-ti¢ed deletions of exons 3 and 4 in both the proband and his father ( Figure 1 and Table 1 ). The absence of any demonstrable abnormality by bidirectional sequencing indicated that the deletion included exons 3 and 4, intron 3 and sections of introns 2 and 4 that extended beyond the primer sites used for PCR ampli¢cation of these exons. The limits of the deletion were identi¢ed by quantitative PCR and dosage analysis followed by sequencing across the deletion junction. A 4,425bp deletion was identi¢ed between IVS2-1987 and IVS4 þ352 with an overlap of just three nucleotides at the breakpoints in introns 2 and 4 ( Figure 2 ).
Unfortunately messenger RNA was not available from this patient to con¢rm the e¡ect of this deletion at the RNA level. However, the deletion causes an arginine to be replaced by a serine at codon 65 and although the amino acid sequence remains in frame, the loss of amino acids that form the upper lip of the active site would almost certainly result in a non-functional enzyme, were it to be produced.
Although over 80 mutations that cause EPP have been identi¢ed in the FECH gene, 2 including one complete gene deletion, 9 this is the ¢rst report of a large, intragenic deletion that does not have a breakpoint within an exon. All previously reported deletions have been intra-exonic and less than 17 bp long. 2 Deletions of the type reported here are undetectable by current gene sequencing strategies, in which only exons and short £anking intronic sequences are ampli¢ed for sequencing. It is possible that the presence of deletions in EPP may, at least partly, explain the low sensitivity of mutation detection in this condition. The way in which gene deletions and partial gene deletions occur is not fully understood, although they often result from recombination events between repetitive elements. Speci¢c sequence characteristics are thought to play a signi¢cant role in this mechanism. For example, palindromic repeats, A--T-rich elements 10 and repeats including repetitive Alu sequence and X-like sequences (GCTGG) 11 have been found to £ank deletion breakpoints in a number of human genetic conditions. The sequence £anking the breakpoints in this patient has been scanned for Alu sequence and other repetitive elements shown previously to be associated with deletions. None were identi¢ed in this case, suggesting that mechanisms other than recombination between repetitive elements account for this deletion.
The persistently raised AST in this patient continues to be monitored as a complication of EPP is progressive liver dysfunction due to accumulation of protoporphyrin in the liver. Monitoring on a regular basis ensures clinical interventions can be initiated when necessary. 1 There is currently no information on factors that increase the risk of liver disease in EPP patients, although the type of mutation does not appear to be involved as the same mutations have been identi¢ed in patients with and without liver disease. 12 In conclusion, overt EPP in our patient was explained by the presence of this FECH deletion trans to the low expression allele IVS3-48C. This work also has wider implications for the investigation of genetic disorders as it shows that the presence of similar deletions should be considered in all patients who are mutationnegative when investigated by methods in which only exons and their immediate £anking regions are analysed.
